Idioma:

Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study

Rannikko, Antti ; Leht, Mare ; Mirtti, Tuomas ; Kenttämies, Anu ; Tolonen, Teemu ; Rinta‐Kiikka, Irina ; Kilpeläinen, Tuomas P. ; Natunen, Kari ; Lilja, Hans ; Lehtimäki, Terho ; Raitanen, Jani ; Kujala, Paula ; Ronkainen, Johanna ; Matikainen, Mika ; Petas, Anssi ; Taari, Kimmo ; Tammela, Teuvo ; Auvinen, Anssi

BJU international, 2022-08, Vol.130 (2), p.193-199 [Periódico revisado por pares]

England: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study
Autor: Rannikko, Antti ; Leht, Mare ; Mirtti, Tuomas ; Kenttämies, Anu ; Tolonen, Teemu ; Rinta‐Kiikka, Irina ; Kilpeläinen, Tuomas P. ; Natunen, Kari ; Lilja, Hans ; Lehtimäki, Terho ; Raitanen, Jani ; Kujala, Paula ; Ronkainen, Johanna ; Matikainen, Mika ; Petas, Anssi ; Taari, Kimmo ; Tammela, Teuvo ; Auvinen, Anssi
Assuntos: 4‐kallikrein panel ; Biopsy ; Cancer and Oncology ; Cancer och onkologi ; Clinical Medicine ; Clinical significance ; Early Detection of Cancer - methods ; Humans ; Image-Guided Biopsy - methods ; Kallikrein ; Kallikreins ; Klinisk medicin ; Magnetic Resonance Imaging ; Male ; Medical and Health Sciences ; Medicin och hälsovetenskap ; multiparametric MRI ; PCSM ; Pilot Projects ; Population-based studies ; Prostate cancer ; Prostate-Specific Antigen ; ProstateCancer ; Prostatic Neoplasms - diagnostic imaging ; randomized trial ; screening ; targeted biopsy ; Urologi och njurmedicin ; Urology and Nephrology ; uroonc
É parte de: BJU international, 2022-08, Vol.130 (2), p.193-199
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Descrição: Objectives To evaluate the feasibility of a population‐based screening trial using prostate‐specific antigen (PSA), a kallikrein panel and multiparametric magnetic resonance imaging (MRI) aimed at minimizing overdiagnosis, while retaining mortality benefit. Patients and Methods Feasibility of the screening algorithm was evaluated in terms of participation, screening test results and cancer detection. A random sample of 400 men aged 65 years was identified from the population registry and invited for screening with three stepwise tests (PSA, kallikrein panel and MRI). Men with PSA levels ≥3 ng/mL were further tested with the kallikrein panel, and those with positive findings (risk >7.5%) were referred for prostate MRI. Men with positive MRI (Prostate Imaging Reporting and Data System [PI‐RADS] score 3–5) had targeted biopsies only. Men with negative MRI, but PSA density ≥0.15 underwent systematic biopsies. Results Of the 399 men invited, 158 (40%) participated and 27 had PSA levels ≥3 ng/mL (7% of the invited and 17% of the participants). Of these, 22 had a positive kallikrein panel (6% of the invited and 81% of the PSA‐positive men). Finally, 10 men (3% of the invited and 45% of 4Kscore [kallikrein panel]‐positive) had a suspicious MRI finding (PI‐RADS score ≥3) and five were diagnosed with a clinically significant prostate cancer (Gleason Grade Group [GG] ≥2) at fusion biopsy (3% of the participants), with two GG 1 cases (1%). Additional testing (kallikrein panel and MRI) after PSA reduced biopsies by 56%. Conclusion The findings constitute proof of principle for our screening protocol, as we achieved a substantial detection rate for clinically significant cancer with few clinically insignificant cases. Participation, however, was suboptimal.
Editor: England: Wiley Subscription Services, Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study

England: Wiley Subscription Services, Inc

Buscando em bases de dados remotas. Favor aguardar.